← Back to Clinical Trials
Recruiting NCT06496555

NCT06496555 Evaluation of U-AKIpredTM for Predicting AKI in Critically Ill Patients Within 12 Hours: a Multicenter Prospective Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06496555
Status Recruiting
Phase
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Condition External Effectiveness Validation of Model
Study Type OBSERVATIONAL
Enrollment 2,100 participants
Start Date 2024-06-01
Primary Completion 2025-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,100 participants in total. It began in 2024-06-01 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of our study is to evaluate U-AKIpredTM for predicting AKI in critically ill patients within 12 h by the multicenter prospective cohorts. AKI was diagnosed by Kidney Disease Improving Global Outcomes (KDIGO) criteria. We designed five aspects including the overall fitting effecience evaluation, calibration curve, quantifying calibration performance, quantifying discrimination performance, quantifying clinical utility to evaluate the external validation model.

Eligibility Criteria

Inclusion Criteria: * critically ill patients who stayed in ICU for over 24 h; * patients older than 18 years of age. Exclusion Criteria: * patients who admitted in ICU had been diagnosed acute kidney injury; * patients who admitted in ICU had been diagnosed acute kidney disease; * patients who admitted in ICU had been diagnosed chronic kidney disease; * patients who admitted in ICU had performed kidney dialysis; * patients who admitted in ICU had performed kidney transplantation; * Pregnant women.

Contact & Investigator

Central Contact

Tao Sun, Doctor

✉ stzr@zju.edu.cn

📞 0571-87783752

Frequently Asked Questions

Who can join the NCT06496555 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying External Effectiveness Validation of Model. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06496555 currently recruiting?

Yes, NCT06496555 is actively recruiting participants. Contact the research team at stzr@zju.edu.cn for enrollment information.

Where is the NCT06496555 trial being conducted?

This trial is being conducted at Hangzhou, China.

Who is sponsoring the NCT06496555 clinical trial?

NCT06496555 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. The trial plans to enroll 2,100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology